News

The trial, which began last month and is scheduled to finish in June 2011, aims to determine whether Antabuse can deplete the pool of residual virus that regular

In the study, consisting of 243 postmenopausal women, nitroglycerin cream demonstrated a capability to increase bone density by about 7% when applied daily to the upper arms for

TRV120027 is a beta-arrestin biased angiotensin II type 1 receptor (AT1R) ligand, the first biased ligand designed to treat patients with AHF. The randomised, placebo-controlled, double-blind, dose-ranging Phase

TXA127 is a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow. Tarix Pharma expects to recruit a

The lab was accredited for being one of a limited number of central labs in the US to meet the rigorous requirements for medical laboratory quality, and competence

The new patent application titled ‘Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer’ gives additional intellectual property protection to the seven antigens used in Immunovaccine’s DPX-0907

Scarguard Labs is a pharmaceutical company specialising in dermatological medications employing an internationally patented delivery system designed to enhance drug effectiveness utilising a multi-technology approach. Scarguard Labs chairman

The integration of DNA shearing technology with automation and microfluidics solutions simplifies next generation sequencing workflows and improves sample quality. Covaris sample preparation technology, which is based on

The Phase 3 trial evaluating the safety and efficacy of rFXIII has showed positive results when compared to a historic control group of individuals who did not receive